EVQLV Wins Columbia Venture Competition

Apr 29, 2020 | News | 0 comments

Daniel Gigante

EVQLV is excited to announce we took first place in Columbia Engineering’s Venture Competition (CVC). We’ve included a snippet from the announcement below. If you’d like to read the official release, you can do so here.

In the Technology Challenge, avoMD and EVQLV each took first place and $20,000 in funding. avoMD, led by cofounders Joongheum Park, Yair Saperstein, and Laurence Coman, is a digital point-of-care personal assistant made for doctors by doctors. EVQLV is an artificial intelligence company focused on accelerating biologic therapies. The company was founded by Andrew Satz and Bret Averso, who aimed to leverage AI to computationally design innovative antibody candidates that can be quickly synthesized and validated. Dialetica, developing wearables for managing advanced-stage kidney failure, placed in third, winning $10,000 in funding.

We would like to give a special thanks to all fellow companies, the wonderful judges, and of course, Columbia Engineering.


Submit a Comment

Your email address will not be published. Required fields are marked *

EVQLV and Manhattan BioSolutions Enter into Strategic Collaboration to Discover Novel Antibody-Based Therapies

The collaboration fuses EVQLV’s expertise in AI-enabled antibody design & Manhattan BioSolutions’ expertise in antibody development in oncology

Demystifying AI In Pharma

Examining AI as automated, assistive, analytical, accelerated, or augmented intelligence is a framework for thinking about how to apply these tools to data in ways that are aligned with an organization’s goals. This framework is designed to allow those who do not routinely build or employ AI to avoid the overhyped rhetoric of AI and consider the practical outcomes of employing it.

Andrew Satz on the Amplifying Scientific Innovation Podcast with Dr. Sophia Ononye-Onyia

EVQLV CEO, Andrew Satz, recently joined the Amplifying Scientific Innovation podcast with Dr. Sophia Ononye-Onyia. They discussed his definition of scientific innovation, personal anecdotes of his CEO journey and EVQLV’s unique approach to scientific innovation through the acceleration of biologic therapies with the power of artificial intelligence (A.I.).

How Our Algorithm Models the Drug Discovery Process

Our CEO, Andrew Satz, recently spoked at “Alumni in Conversation,” hosted by Columbia University School of General Studies. During the discussion, Andrew explained how EVQLV’s algorithm models the drug discovery process.

Large Pharma’s Embrace of Artificial Intelligence

The benefits of computational drug development are well known and accepted by many in the pharmaceutical space. However, since the onset of the global pandemic, consensus went from it being an interesting concept that was almost certainly the future, to something we need implemented as soon as possible. This is one of the few silver linings of the coronavirus outbreak.

Pin It on Pinterest